News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website

 

Vion Says Pediatric Tumor Study Begins


Posted on: 04/13/2005

Vion Says Pediatric Tumor Study Begins

Associated Press
04.13.2005, 09:47 AM

Vion Pharmaceuticals Inc., a cancer drug developer, said Wednesday that a group of hospitals specializing in treating children's brain tumors has begun an early-stage clinical study of its cancer-fighting drug, Cloretazine.

The Pediatric Brain Tumor Consortium - comprising leading academic and children's hospitals around the country - will conduct the study, which will gauge the effects of Cloretazine in children with recurrent, progressive or refractory primary brain tumors, the company said.

Vion said its drug aims to circumvent drug resistance in tumors, the usual cause of treatment failure in children with recurrent malignant brain tumors.

The company's shares fell 7 cents, or 2.6 percent, to $2.60 in morning trading on the Nasdaq.


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740